Cellebrite's digital intelligence platform demonstrates durable demand with revenue growth moderating to 15.8% in 2026Q2, supported by a high-margin software model yielding 80.8% gross margins. The company's fortress balance sheet, with a debt-to-equity ratio ...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | $0.03-56.7% vs $0.06 | $131M-0.3% vs $132M |
Q2 2026 May 14, 2026 | $0.04-25.6% vs $0.05 | $128M+1.0% vs $127M |
Q1 2026 Feb 11, 2026 | $0.09-38.1% vs $0.14 | $129M+2.1% vs $126M |
Q4 2025 Nov 12, 2025 | $0.08-15.3% vs $0.09 | $126M+2.5% vs $123M |
New York, New York--(Newsfile Corp. - September 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ: CLBT).
Law&Crime Network and NewsNation anchor Jesse Weber returns to host; ceremony to stream live to Law&Crime Network's 7.7 million YouTube subscribers during Cellebrite's annual C2C User Summit in April 2027 TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept.
Squarepoint Ops LLC lessened its stake in Cellebrite DI Ltd. (NASDAQ: CLBT) by 49.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,185 shares of the company's stock after selling 66,713 shares during the quarter. Squarepoint Ops
/PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), ein weltweit führender Anbieter von KI-gestützten Lösungen für digitale Ermittlungen und
Benchmark CLBT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cellebrite DI Ltd. (CLBT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.14 | $2.78B | 35.94 | 18.56% | 16.47% | 19.1% | — | |
| $422.21 | $34.03B | 279.61 | 33.47% | 6.2% | 5.92% | — | |
| $47.45 | $5.45B | -41.99 | 13.17% | -20.55% | -26.91% | — | |
| $18.04 | $668.8M | 9.49 | 0% | 27.76% | 25.92% | — | |
| $40.33 | $2.93B | 31.02 | 4.47% | 13.71% | 7.42% | — | |
| $14.46 | $345.43M | 25.81 | -7.29% | 4.9% | 2.33% | — |
Cellebrite DI Ltd. (CLBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CLBT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cellebrite DI Ltd. (CLBT) stock FAQ — growth, dividends, profitability & financials explained
Cellebrite DI Ltd. (CLBT) reported $514.3M in revenue for fiscal year 2025. This represents a 199% increase from $171.9M in 2019.
Cellebrite DI Ltd. (CLBT) grew revenue by 18.6% over the past year. This is strong growth.
Yes, Cellebrite DI Ltd. (CLBT) is profitable, generating $58.8M in net income for fiscal year 2025 (16.5% net margin).
Cellebrite DI Ltd. (CLBT) has a return on equity (ROE) of 19.1%. This is reasonable for most industries.
Cellebrite DI Ltd. (CLBT) generated $139.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
